MCID: EST001
MIFTS: 52

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 14

Classifications:



External Ids:

Disease Ontology 12 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to estrogen-receptor negative breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Anastrozole and Exemestane have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 173)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor negative breast cancer 30.6 ERBB2 ESR1 FOXA1 PGR
2 breast cancer 28.3 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
3 lung cancer 28.1 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
4 scirrhous adenocarcinoma 10.6 ERBB2 PGR
5 breast apocrine carcinoma 10.6 ERBB2 PGR
6 vulvar syringoma 10.6 ESR1 PGR
7 breast papillomatosis 10.6 CCND1 ERBB2
8 endometrial clear cell adenocarcinoma 10.6 ESR1 TP53
9 endometrium carcinoma in situ 10.6 PGR TP53
10 lung leiomyoma 10.6 ESR1 PGR
11 vulvar benign neoplasm 10.5 ESR1 PGR
12 trigonitis 10.5 ESR1 PGR
13 vulvar leiomyoma 10.5 ESR1 PGR
14 predominantly cortical thymoma 10.5 ESR1 PGR
15 glassy cell carcinoma of the cervix 10.5 ERBB2 ESR1 PGR
16 adult hepatocellular carcinoma 10.5 PIK3CA TP53
17 comedo carcinoma 10.5 ERBB2 ESR1
18 breast medullary carcinoma 10.5 ERBB2 ESR1 PGR
19 vestibular gland benign neoplasm 10.5 ESR1 PGR TP53
20 bartholin's gland adenoma 10.5 ESR1 PGR TP53
21 apocrine adenocarcinoma 10.5 ERBB2 ESR1 PGR
22 non-proliferative fibrocystic change of the breast 10.5 CCND1 ERBB2 TP53
23 endometrial squamous cell carcinoma 10.5 CCND1 ESR1 PGR
24 bartholin's gland benign neoplasm 10.4 ESR1 PGR TP53
25 malignant spiradenoma 10.4 PIK3CA TP53
26 cervical carcinosarcoma 10.4 ESR1 PGR TP53
27 uterine corpus serous adenocarcinoma 10.4 ERBB2 TP53
28 bilateral breast cancer 10.4 ERBB2 ESR1 PGR
29 breast papillary carcinoma 10.4 ERBB2 ESR1 PGR
30 glycogen-rich clear cell breast carcinoma 10.4 ESR1 PGR TP53
31 triple-receptor negative breast cancer 10.4 ERBB2 ESR1 PGR
32 uterine body mixed cancer 10.4 ERBB2 PGR TP53
33 adenosarcoma 10.4 ESR1 PGR TP53
34 dermatosis papulosa nigra 10.4 MTOR PIK3CA
35 breast intraductal proliferative lesion 10.4 EGFR ERBB2
36 glioma susceptibility 1 10.4 ERBB2 TP53
37 pancreatic neuroendocrine tumor 10.4 MTOR PIK3CA
38 brain ependymoma 10.4 EGFR TP53
39 bent bone dysplasia syndrome 10.4 ERBB2 FGFR2
40 progesterone resistance 10.4 ESR1 PGR
41 gender identity disorder 10.3 CYP19A1 ESR1 PGR
42 hemimegalencephaly 10.3 CCND1 MTOR PIK3CA
43 estrogen excess 10.3 CYP19A1 ESR1 PGR
44 mammographic density 10.3 CYP19A1 ESR1 PGR
45 angiomyolipoma 10.3 ESR1 MTOR PGR
46 endometriosis of ovary 10.3 CYP19A1 ESR1 PGR
47 juvenile nasopharyngeal angiofibroma 10.3 CYP19A1 ESR1 PGR
48 female reproductive endometrioid cancer 10.3 PGR TP53
49 breast benign neoplasm 10.3 ERBB2 ESR1 PGR TP53
50 thoracic benign neoplasm 10.3 ERBB2 ESR1 PGR TP53

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

25 (show top 50) (show all 60)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.54 MTOR PIK3CA EGFR
2 Decreased viability GR00107-A-1 10.54 HSPB8
3 Decreased viability GR00221-A-1 10.54 PIK3CA MTOR AKT1 EGFR ESR1 HSPB8
4 Decreased viability GR00221-A-2 10.54 PIK3CA AKT1 ESR1
5 Decreased viability GR00221-A-3 10.54 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.54 PIK3CA MTOR AKT1 EGFR ERBB2 ESR1
7 Decreased viability GR00301-A 10.54 HSPB8
8 Decreased viability GR00342-S-1 10.54 MTOR
9 Decreased viability GR00342-S-2 10.54 MTOR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.32 FOXA1
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.32 PIK3CA FOXA1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.32 CCND1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.32 MTOR
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.32 CCND1
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.32 CCND1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.32 PIK3CA CCND1 FOXA1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.32 RAB31
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.32 FOXA1
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.32 PIK3CA MTOR RAB31 CCND1 FOXA1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.32 PIK3CA MTOR
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.32 CCND1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.21 MTOR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.21 MTOR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.21 FOXA1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.21 CCND1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.21 FOXA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.21 NCOA3
28 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.21 FOXA1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.21 NCOA3
30 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.21 CCND1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.21 PIK3CA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 PIK3CA MTOR AKT1 CCND1 FOXA1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 CCND1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.21 PIK3CA
35 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.21 PIK3CA NCOA3 AKT1 CCND1 FOXA1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.21 FOXA1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.21 PIK3CA
38 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.21 CCND1
39 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.21 FOXA1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.21 CCND1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.21 CCND1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 FOXA1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 CCND1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 CCND1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.21 PIK3CA MTOR AKT1 FOXA1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.21 PIK3CA
47 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.21 AKT1
48 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 FOXA1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.21 AKT1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.21 MTOR

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

43 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.43 FGFR2 MTOR HSPB8 NCOA3 PIK3CA PGR
2 endocrine/exocrine gland MP:0005379 10.4 MTOR FOXA1 NCOA3 PGR STAT5B PIK3CA
3 homeostasis/metabolism MP:0005376 10.4 HSPB8 FGFR2 MTOR FOXA1 NCOA3 PIK3CA
4 behavior/neurological MP:0005386 10.38 FGFR2 MTOR NCOA3 PIK3CA PGR TP53
5 cardiovascular system MP:0005385 10.37 HSPB8 FGFR2 MTOR PIK3CA PGR TP53
6 growth/size/body region MP:0005378 10.36 FGFR2 MTOR FOXA1 NCOA3 PIK3CA TP53
7 immune system MP:0005387 10.36 FGFR2 MTOR FOXA1 HSPB8 PIK3CA PGR
8 integument MP:0010771 10.31 FOXA1 NCOA3 FGFR2 PIK3CA PGR STAT5B
9 adipose tissue MP:0005375 10.3 MTOR FGFR2 PIK3CA STAT5B NCOA3 TP53
10 mortality/aging MP:0010768 10.3 HSPB8 FGFR2 MTOR FOXA1 NCOA3 PIK3CA
11 hematopoietic system MP:0005397 10.28 FGFR2 MTOR NCOA3 PGR STAT5B TP53
12 embryo MP:0005380 10.27 FGFR2 MTOR NCOA3 PIK3CA PGR TP53
13 digestive/alimentary MP:0005381 10.23 FGFR2 FOXA1 NCOA3 TP53 CYP19A1 CCND1
14 muscle MP:0005369 10.21 MTOR HSPB8 FGFR2 PIK3CA PGR NCOA3
15 neoplasm MP:0002006 10.14 FOXA1 NCOA3 FGFR2 PIK3CA PGR TP53
16 normal MP:0002873 10.1 FGFR2 MTOR PGR STAT5B NCOA3 TP53
17 liver/biliary system MP:0005370 10.08 FGFR2 NCOA3 TP53 STAT5B AKT1 CYP19A1
18 reproductive system MP:0005389 9.93 FGFR2 NCOA3 PIK3CA PGR STAT5B TP53
19 no phenotypic analysis MP:0003012 9.91 FGFR2 MTOR PIK3CA PGR TP53 EGFR
20 renal/urinary system MP:0005367 9.86 FGFR2 MTOR NCOA3 TP53 STAT5B CYP19A1
21 respiratory system MP:0005388 9.61 HSPB8 FGFR2 MTOR TP53 AKT1 CCND1
22 skeleton MP:0005390 9.4 FGFR2 MTOR NCOA3 PIK3CA PGR TP53

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 206)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 120511-73-1 2187
2
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 107868-30-4 60198
3
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 129453-61-8 17756771 104741
4
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
5
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1 10540-29-1 2733526
6
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
7
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
9 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
10 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
11 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
12 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
13 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1
14 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
16 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
18 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
19 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
21 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1
22 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
23 Antifungal Agents Phase 4,Phase 3,Phase 2
24 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
25
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
26
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
27
Epirubicin Approved Phase 3 56420-45-2 41867
28
Fluorouracil Approved Phase 3 51-21-8 3385
29
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1 57-83-0 5994
30
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
31
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 50-28-2 5757
32
Metformin Approved Phase 3,Phase 2 657-24-9 4091 14219
33
Goserelin Approved Phase 3,Phase 2 65807-02-5 5311128 47725
34
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
35
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 5330286 11431660 5005498
36
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
37
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
38
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
39
Pertuzumab Approved Phase 3 380610-27-5, 145040-37-5 2540
40
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
41
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
42
Norepinephrine Approved Phase 3 51-41-2 439260
43
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
44
Methyltestosterone Approved Phase 3 58-18-4 6010
45
Testosterone Approved, Investigational Phase 3 58-22-0 6013
46
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 77-92-9 311
47
Cholecalciferol Approved, Nutraceutical Phase 2, Phase 3 67-97-0 10883523 5280795 6221
48
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
49
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
50
Docetaxel Approved May 1996, Investigational Phase 3 114977-28-5 148124 9877265

Interventional clinical trials:

(show top 50) (show all 146)

# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
4 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Unknown status NCT01104571 Phase 3 lapatinib ditosylate
5 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
6 Prevalence of Genetic Polymorphisms in Genes Coding for Tamoxifen Metabolising Enzymes Completed NCT00966043 Phase 3
7 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
8 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
9 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
10 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
11 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
12 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
13 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Recruiting NCT02947685 Phase 3 palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
14 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Recruiting NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
15 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
16 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
17 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
18 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
19 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
20 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
21 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Active, not recruiting NCT01598298 Phase 3 duloxetine hydrochloride
22 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
23 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
24 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
25 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
26 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
27 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
28 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
29 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
30 Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
31 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
32 Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Unknown status NCT01589367 Phase 2 Metformin;Placebo
33 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
34 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
35 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
36 Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
37 Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Completed NCT00093002 Phase 2 Fulvestrant
38 A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
39 Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
40 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
41 Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
42 AKT Inhibitor in Oestrogen Positive Breast Cancer Completed NCT02077569 Phase 2 AZD5363
43 Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers Completed NCT00467493 Phase 2 Anastrozole
44 Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer Completed NCT00676663 Phase 2 entinostat;exemestane
45 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed NCT00057941 Phase 2 anastrozole;gefitinib;fulvestrant
46 F-18 16 Alpha-Fluoroestradiol-Labeled Positron Emission Tomography in Predicting Response to First-Line Hormone Therapy in Patients With Stage IV Breast Cancer Completed NCT00602043 Phase 2
47 Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer Completed NCT00082810 Phase 2 fulvestrant;tipifarnib
48 Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery Completed NCT00407888 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel albumin-stabilized nanoparticle formulation
49 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
50 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

38
Breast, Bone, Lymph Node, Testes, Brain, Skin, Kidney

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 380)
# Title Authors Year
1
miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. ( 29247596 )
2018
2
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( 29202611 )
2018
3
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 29450494 )
2018
4
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. ( 29128895 )
2018
5
Omega-3 Polyunsaturated Fatty Acids Time-Dependently Reduce Cell Viability and Oncogenic MicroRNA-21 Expression in Estrogen Receptor-Positive Breast Cancer Cells (MCF-7). ( 29342901 )
2018
6
Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. ( 29373839 )
2018
7
Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk. ( 29445914 )
2018
8
A New Class of Agents for Estrogen-Receptor-Positive Breast Cancer. ( 29439601 )
2018
9
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. ( 29436393 )
2018
10
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. ( 29363090 )
2018
11
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. ( 29352052 )
2018
12
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. ( 29127189 )
2018
13
Wnt7a Deficiency Could Predict Worse Disease-Free and Overall Survival in Estrogen Receptor-Positive Breast Cancer. ( 29285041 )
2017
14
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer. ( 28270497 )
2017
15
MUC1 induces tamoxifen resistance in estrogen receptor-positive breast cancer. ( 28597750 )
2017
16
Identify high risk estrogen receptor-positive breast cancer patients for extended endocrine therapy. ( 27866092 )
2017
17
Androgen receptor in estrogen receptor positive breast cancer: Beyond expression. ( 29078133 )
2017
18
HDAC2 and HDAC5 Up-Regulations Modulate Survivin and miR-125a-5p Expressions and Promote Hormone Therapy Resistance in Estrogen Receptor Positive Breast Cancer Cells. ( 29326587 )
2017
19
Targeting cell necroptosis and apoptosis induced by Shikonin via receptor interacting protein kinases in estrogen receptor positive breast cancer cell line, MCF-7. ( 28933271 )
2017
20
Activation of hypoxia-inducible factor-1I+ by prolonged inA vivo hyperinsulinemia treatment potentiates cancerous progression in estrogen receptor-positive breast cancer cells. ( 28351619 )
2017
21
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer. ( 28447240 )
2017
22
Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. ( 28795152 )
2017
23
High tumor-infiltrating FoxP3(+) T cells predict poor survival in estrogen receptor-positive breast cancer: A meta-analysis. ( 28214052 )
2017
24
miR-125a-3p inhibits ERI+ transactivation and overrides tamoxifen resistance by targeting CDK3 in estrogen receptor-positive breast cancer. ( 28939591 )
2017
25
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer. ( 28581884 )
2017
26
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. ( 28324268 )
2017
27
Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones. ( 28791495 )
2017
28
Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen. ( 28852212 )
2017
29
Leptin is overexpressed in the tumor microenvironment of obese patients with estrogen receptor positive breast cancer. ( 28565832 )
2017
30
BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy. ( 29325860 )
2017
31
Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells. ( 28637868 )
2017
32
PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. ( 28347547 )
2017
33
Patterns of Progression in Metastatic Estrogen Receptor Positive Breast Cancer: An Argument for Local Therapy. ( 29147583 )
2017
34
21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer. ( 28702894 )
2017
35
Can (18)F-Fluoroestradiol Positron Emission Tomography Become a New Imaging Standard in the Estrogen Receptor-positive Breast Cancer Patient: A Prospective Comparative Study with (18)F-Fluorodeoxyglucose Positron Emission Tomography? ( 28553180 )
2017
36
Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. ( 28147342 )
2017
37
Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. ( 28415819 )
2017
38
Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers. ( 28929082 )
2017
39
Endocrine sensitivity of estrogen receptor-positive breast cancer is negatively correlated with aspartate-I^-hydroxylase expression. ( 28985022 )
2017
40
Genetic and environmental factors and serum hormones, and risk of estrogen receptor-positive breast cancer in pre- and postmenopausal Japanese women. ( 29029469 )
2017
41
Anti-cancer stem cell activity of a hedgehog inhibitor GANT61 in estrogen receptor-positive breast cancer cells. ( 28211214 )
2017
42
Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Project B-28 and B-14. ( 27217450 )
2016
43
Somatic mutation, copy number and transcriptomic profiles of primary and matched metastatic estrogen receptor-positive breast cancers. ( 27672107 )
2016
44
MiR-206 suppresses epithelial mesenchymal transition by targeting TGF-I^ signaling in estrogen receptor positive breast cancer cells. ( 27014911 )
2016
45
CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression. ( 26812885 )
2016
46
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. ( 27367583 )
2016
47
The Experience of Initiating Oral Adjuvant Treatment for Estrogen Receptor-Positive Breast Cancer. ( 27314197 )
2016
48
Correction: Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer. ( 27698190 )
2016
49
Lifetime body size and estrogen-receptor-positive breast cancer risk in the California Teachers Study cohort. ( 28003027 )
2016
50
Cholesterol biosynthesis pathway as a novel mechanism of resistance to estrogen deprivation in estrogen receptor-positive breast cancer. ( 27246191 )
2016

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.26 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
2
Show member pathways
13.9 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
3
Show member pathways
13.8 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
4
Show member pathways
13.73 AKT1 EGFR ERBB2 FGFR2 MTOR NCOA3
5
Show member pathways
13.62 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
6
Show member pathways
13.49 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
7
Show member pathways
13.45 AKT1 CCND1 EGFR ERBB2 FGFR2 PIK3CA
8
Show member pathways
13.3 AKT1 CCND1 EGFR ERBB2 MTOR STAT5B
9
Show member pathways
13.21 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
10
Show member pathways
13.1 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
11
Show member pathways
13.07 AKT1 CCND1 EGFR FGFR2 MTOR PIK3CA
12
Show member pathways
12.87 AKT1 CCND1 PIK3CA STAT5B TP53
13
Show member pathways
12.85 AKT1 CCND1 MTOR PIK3CA STAT5B
14
Show member pathways
12.82 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
15
Show member pathways
12.81 AKT1 ERBB2 ESR1 MTOR PIK3CA TP53
16
Show member pathways
12.77 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
17
Show member pathways
12.69 AKT1 EGFR ERBB2 PIK3CA STAT5B TP53
18
Show member pathways
12.67 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
19 12.62 CCND1 EGFR ERBB2 MTOR PIK3CA TP53
20
Show member pathways
12.58 AKT1 EGFR ERBB2 MTOR PIK3CA TP53
21
Show member pathways
12.56 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
22
Show member pathways
12.54 AKT1 CCND1 MTOR PIK3CA TP53
23
Show member pathways
12.54 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
24
Show member pathways
12.54 AKT1 CCND1 EGFR ERBB2 ESR1 MTOR
25 12.53 AKT1 CCND1 PIK3CA STAT5B TP53
26
Show member pathways
12.51 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA
27
Show member pathways
12.49 AKT1 FGFR2 MTOR PIK3CA
28
Show member pathways
12.49 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
29
Show member pathways
12.49 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
30
Show member pathways
12.47 AKT1 EGFR MTOR PIK3CA
31
Show member pathways
12.45 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
32 12.42 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
33
Show member pathways
12.39 AKT1 EGFR ERBB2 PIK3CA
34 12.37 CCND1 PIK3CA STAT5B TP53
35
Show member pathways
12.36 AKT1 CCND1 EGFR ERBB2 ESR1 NCOA3
36
Show member pathways
12.34 AKT1 MTOR STAT5B TP53
37
Show member pathways
12.31 CCND1 ESR1 NCOA3 PGR
38 12.31 AKT1 CCND1 EGFR ERBB2 ESR1 MTOR
39 12.28 AKT1 CCND1 EGFR TP53
40 12.28 AKT1 EGFR ERBB2 MTOR NCOA3 STAT5B
41
Show member pathways
12.27 AKT1 MTOR PIK3CA TP53
42 12.27 AKT1 CCND1 MTOR PIK3CA TP53
43
Show member pathways
12.26 AKT1 FGFR2 MTOR PIK3CA
44
Show member pathways
12.26 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
45
Show member pathways
12.23 AKT1 EGFR ERBB2 PIK3CA
46
Show member pathways
12.23 AKT1 MTOR PIK3CA TP53
47
Show member pathways
12.18 AKT1 CCND1 EGFR PIK3CA
48
Show member pathways
12.18 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA
49 12.16 AKT1 CCND1 MTOR TP53
50
Show member pathways
12.16 AKT1 CCND1 EGFR ERBB2

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.36 AKT1 CCND1 ESR1 FGFR2 FOXA1 HSPB8
2 phosphatidylinositol 3-kinase complex GO:0005942 8.96 MTOR PIK3CA

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 peptidyl-tyrosine phosphorylation GO:0018108 9.92 EGFR ERBB2 FGFR2 STAT5B
2 protein autophosphorylation GO:0046777 9.91 AKT1 EGFR ERBB2 FGFR2 MTOR
3 positive regulation of transcription by RNA polymerase II GO:0045944 9.91 AKT1 EGFR ESR1 FGFR2 FOXA1 NCOA3
4 positive regulation of protein phosphorylation GO:0001934 9.88 AKT1 CCND1 EGFR ERBB2 MTOR
5 lung development GO:0030324 9.86 EGFR FGFR2 FOXA1
6 liver development GO:0001889 9.85 CCND1 EGFR PIK3CA
7 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.84 AKT1 EGFR PIK3CA
8 positive regulation of cell growth GO:0030307 9.84 AKT1 EGFR ERBB2
9 phosphatidylinositol phosphorylation GO:0046854 9.84 EGFR ERBB2 FGFR2 PIK3CA
10 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 FGFR2
11 epidermal growth factor receptor signaling pathway GO:0007173 9.81 AKT1 EGFR PIK3CA
12 positive regulation of protein kinase B signaling GO:0051897 9.8 EGFR ERBB2 FGFR2 MTOR PIK3CA
13 positive regulation of nitric oxide biosynthetic process GO:0045429 9.79 AKT1 EGFR MTOR
14 positive regulation of cell cycle GO:0045787 9.78 CCND1 FGFR2 TP53
15 ERBB2 signaling pathway GO:0038128 9.77 EGFR ERBB2 PIK3CA
16 cellular response to estradiol stimulus GO:0071392 9.77 EGFR ESR1 NCOA3
17 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 AKT1 EGFR FGFR2 MTOR
18 cellular response to reactive oxygen species GO:0034614 9.75 AKT1 EGFR TP53
19 phosphatidylinositol 3-kinase signaling GO:0014065 9.74 AKT1 ERBB2 PIK3CA
20 regulation of ERK1 and ERK2 cascade GO:0070372 9.73 EGFR ERBB2 FGFR2
21 cellular response to growth factor stimulus GO:0071363 9.73 AKT1 EGFR ERBB2 STAT5B
22 regulation of multicellular organism growth GO:0040014 9.72 FGFR2 PIK3CA STAT5B
23 negative regulation of ERBB signaling pathway GO:1901185 9.69 EGFR ERBB2
24 TOR signaling GO:0031929 9.69 AKT1 MTOR
25 positive regulation of lipid biosynthetic process GO:0046889 9.68 AKT1 MTOR
26 positive regulation of transcription by RNA polymerase III GO:0045945 9.67 ERBB2 MTOR
27 negative regulation of macroautophagy GO:0016242 9.67 AKT1 MTOR PIK3CA
28 negative regulation of cell size GO:0045792 9.66 AKT1 MTOR
29 mitotic G1 DNA damage checkpoint GO:0031571 9.65 CCND1 TP53
30 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.65 AKT1 EGFR
31 regulation of glycogen biosynthetic process GO:0005979 9.64 AKT1 MTOR
32 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.64 ESR1 FGFR2
33 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.63 ESR1 FGFR2
34 cellular response to epidermal growth factor stimulus GO:0071364 9.62 AKT1 EGFR ERBB2 STAT5B
35 prostate epithelial cord elongation GO:0060523 9.58 ESR1 FGFR2
36 response to estradiol GO:0032355 9.55 CCND1 EGFR ESR1 FOXA1 STAT5B
37 anoikis GO:0043276 9.54 AKT1 MTOR PIK3CA
38 wound healing GO:0042060 9.35 EGFR ERBB2 FGFR2 MTOR TP53
39 response to UV-A GO:0070141 8.8 AKT1 CCND1 EGFR
40 phosphorylation GO:0016310 10.1 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
41 regulation of transcription by RNA polymerase II GO:0006357 10.08 EGFR ERBB2 ESR1 FOXA1 STAT5B
42 positive regulation of cell proliferation GO:0008284 10.07 AKT1 CCND1 EGFR FGFR2 STAT5B
43 protein phosphorylation GO:0006468 10.07 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.92 AKT1 EGFR ERBB2 ESR1 HSPB8 MTOR
2 kinase activity GO:0016301 9.91 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
3 nucleotide binding GO:0000166 9.88 AKT1 EGFR ERBB2 FGFR2 MTOR
4 protein kinase binding GO:0019901 9.88 AKT1 CCND1 EGFR ESR1 MTOR TP53
5 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.84 ESR1 FOXA1 PGR STAT5B
6 protein tyrosine kinase activity GO:0004713 9.73 EGFR ERBB2 FGFR2 STAT5B
7 enzyme binding GO:0019899 9.73 AKT1 CCND1 EGFR ESR1 PGR TP53
8 protein phosphatase binding GO:0019903 9.69 EGFR ERBB2 TP53
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 EGFR ERBB2 FGFR2
10 signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.52 EGFR ERBB2
11 protein kinase activity GO:0004672 9.5 AKT1 CCND1 EGFR ERBB2 FGFR2 HSPB8
12 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.46 EGFR ERBB2 FGFR2 PIK3CA
13 nitric-oxide synthase regulator activity GO:0030235 8.8 AKT1 EGFR ESR1
14 transferase activity GO:0016740 10.1 AKT1 EGFR ERBB2 FGFR2 MTOR NCOA3

Sources for Estrogen-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....